Drug Safety Alert: DRAP and DDCP Order Recall of Substandard Medications
The Drug Regulatory Authority of Pakistan (DRAP) and the Directorate of Drugs Control Punjab (DDCP) have jointly issued medicine recall alerts in 2026, identifying several substandard and adulterated medicines in Punjab, Pakistan. The affected products include Dormicum, Davidax, Zeftrox, PSOL 2mL, PSOL 10mL, Telosin Capsule SR 0.4mg, and Bisgit 5mg Tablet, with DRAP and DDCP directing relevant stakeholders to take necessary precautionary and regulatory measures to ensure public safety.
Recall Alert: Medicine Products Declared Substandard and Adulterated by Drug Testing Laboratories, Punjab
DDCP Alert No.: 160/2026
Date: 13.11.2026
Recall Classification: Class-I
Problem Statement
The Drug Testing Laboratories (DTLs), Punjab, have declared the following pharmaceutical products as Substandard and Adulterated. Accordingly, the Provincial Quality Control Board, Punjab, has directed the issuance of a recall for the affected products.
Details of Affected Products
1. Injection Dormicum
Composition: Each ampoule contains Midazolam 5mg/5ml.
Registration No.: 014929
Batch Numbers: 47447 and 47661
Expiry Date: Apr-2028
Manufacturer: M/s Martin Dow Marker Ltd., 7, Jail Road, Quetta, Pakistan.
Quality Defect: Declared Substandard due to the presence of visible particulate matter.
TRA Numbers: TRA No.01-118002523/DTL and TRA No.01-118002536/DTL.
Date of Testing Report: 12.11.2026.
2. Injection Davidax
Composition: Each mL contains Dexamethasone Sodium Phosphate equivalent to Dexamethasone Phosphate 4mg.
Registration No.: 121545
Batch No.: DDI126
Expiry Date: Mar-2028
Manufacturer: M/s Unison Chemical Works, 15 Km, Raiwind Road, Lahore, Pakistan.
Quality Defect: Declared Adulterated.
TRA No.: TRA No.01-68037977/DTL.
Date of Testing Report: 11.11.2026.
3. Injection Zeftrox
Composition: Each vial contains Ceftriaxone Sodium equivalent to 500mg of Ceftriaxone.
Registration No.: 022224
Batch No.: 677
Expiry Date: Feb-2028
Manufacturer: M/s Zafa Pharmaceutical Laboratories (Pvt.) Ltd., Plot No. B-10, Block-B, S.I.T.E., North Karachi, Karachi, Pakistan.
Quality Defect: Declared Substandard on the basis of the Sterility Test.
TRA No.: TRA No.01-68037949/DTL.
Date of Testing Report: 06.11.2026.
4. Injection PSOL 2mL
Composition: Sterile Water for Injection, 2mL/Ampoule (as a diluent).
Registration No.: 098431
Batch No.: AK164
Expiry Date: Dec-2028
Manufacturer: M/s Pharmasol Private Ltd., Plot No. 549, Sundar Industrial Estate, Lahore, Pakistan.
Quality Defect: Declared Substandard on the basis of the Sterility Test.
TRA No.: TRA No.01-118000999/DTL.
Date of Testing Report: 18.07.2026.
5. Injection PSOL 10mL
Composition: Sterile Water for Injection, 10mL/Ampoule (as a diluent).
Registration No.: 098433
Batch No.: VL277
Expiry Date: Mar-2029
Manufacturer: M/s Pharmasol Private Ltd., Plot No. 549, Sundar Industrial Estate, Lahore, Pakistan.
Quality Defect: Declared Substandard due to the presence of visible particulate matter.
TRA No.: TRA No.01-141006630/DTL.
Date of Testing Report: 18.07.2026.
2. Recall Alert No. 54: Drug Products Declared Substandard by Drug Testing Laboratories, Punjab
DRAP Alert No.: No II/S/11-26-54
Action Date: 16th November, 2026
Recall Classification: Class-II
Problem Statement
The Drug Testing Laboratories (DTLs) of Punjab Province have reported that samples of the following pharmaceutical products have been declared Substandard. The affected products and their respective details are provided below.
Therapeutic Goods Affected
1. Telosin Capsule SR 0.4mg
Composition: Tamsulosin Hydrochloride sustained-release pellets equivalent to Tamsulosin 0.4mg.
Manufacturer: Briell Pharmaceuticals (Pvt.) Ltd., 538-C Sunder Industrial Estate, Lahore.
Batch No.: 57026.
Quality Defect: Declared Substandard by Drug Testing Laboratory (DTL), Punjab, Multan, on the basis of impurity testing.
2. Bisgit 5mg Tablet
Composition: Each film-coated tablet contains Bisoprolol Fumarate.
Manufacturer: Glitz Pharma, Plot No. 265, Industrial Triangle, Kahuta Road, Islamabad.
Batch No.: T12426.
Quality Defect: Declared Substandard by Drug Testing Laboratory (DTL), Punjab, Rawalpindi, due to the detection of additional peaks during assay testing.
Risk Statement
The use of the aforementioned substandard drug products may result in serious health consequences for patients, as the effects of the impurities and other unidentified substances present in these products are unknown.
Get Free Study Notes
1. Action Initiated
DRAP and the DDCP have directed their field forces to conduct immediate market surveys and ensure the removal of affected batches. Manufacturers, importers and distributors have also been instructed to initiate recalls in accordance with regulatory requirements.
2. Directions for Manufacturers, MAHs and Distributors
Immediately recall the affected batches from the market.
Provide complete distribution records and ensure removal of the affected products.
Conduct root cause analysis, prepare a Corrective and Preventive Action (CAPA) plan, and submit the required documentation to the concerned regulatory authorities.
3. Directions for Pharmacies, Medical Stores and Healthcare Facilities
Immediately stop dispensing and supplying the affected batches.
Check existing stocks and maintain inventory and consumption records.
Report available stocks to the respective Drug Inspectors.
4. Directions for Doctors and Healthcare Professionals
Avoid prescribing, dispensing or administering the affected batches.
Exercise caution regarding the use of the identified products.
Report any suspected adverse drug reactions (ADRs) to the relevant pharmacovigilance authorities.
5. Directions for Consumers and General Public
Immediately discontinue the use of the affected medicine batches.
Seek guidance from healthcare professionals regarding their replacement.
Report any suspected adverse reactions associated with these products to the relevant pharmacovigilance authorities, using ADR reporting form or Online from VigiMobile App
6. Regulatory Surveillance and Compliance
DRAP and DDCP have been directed to strengthen market surveillance, ensure the effective recall of affected batches, and take appropriate regulatory action under the Drugs Act 1976, DRAP Act 2012, and rules framed thereunder. DDCP Punjab has also directed its field formations to submit a comprehensive report to the Chief Drugs Controller, Punjab.
References:
1. Drug Regulatory Authority of Pakistan. (2026, November 16). 54. Recall alert: Drug products declared substandard by Drug Testing Laboratories Punjab. https://www.dra.gov.pk/safety_info/product_recalls/recall_alerts/54-recall-alert-drug-products-declared-substandard-by-drug-testing-laboratories-punjab/
2. Directorate of Drugs Control Punjab. (n.d.). Directorate of Drugs Control Punjab [Facebook page]. Facebook. Retrieved November 16, 2026, from https://www.facebook.com/DDC.Punjab
Disclaimer
This article is prepared for informational and educational purposes only and is based on official drug safety alerts issued by the Drug Regulatory Authority of Pakistan (DRAP) and DDCP.
The information should not be considered medical advice, a substitute for professional consultation, or an independent laboratory assessment of the identified products

